| 1 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 2 |
Kuffler DP. Variables affecting the potential efficacy of PRP in providing chronic pain relief. J Pain Res 2019;12:109-16. [PMID: 30613159 DOI: 10.2147/JPR.S190065] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 3 |
Vilar JM, Manera ME, Santana A, Spinella G, Rodriguez O, Rubio M, Carrillo JM, Sopena J, Batista M. Effect of leukocyte-reduced platelet-rich plasma on osteoarthritis caused by cranial cruciate ligament rupture: A canine gait analysis model. PLoS One 2018;13:e0194752. [PMID: 29554150 DOI: 10.1371/journal.pone.0194752] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 4 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
| 5 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
| 6 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
| 7 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
| 8 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
| 9 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
| 10 |
El Bakly W, Medhat M, Shafei M, Tash R, Elrefai M, Shoukry Y, Omar NN. Optimized platelet rich plasma releasate (O-rPRP) repairs galactosemia-induced ovarian follicular loss in rats by activating mTOR signaling and inhibiting apoptosis. Heliyon 2020;6:e05006. [PMID: 33005806 DOI: 10.1016/j.heliyon.2020.e05006] [Reference Citation Analysis]
|
| 11 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
| 12 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
| 13 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
| 14 |
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci 2020;21:E7794. [PMID: 33096812 DOI: 10.3390/ijms21207794] [Reference Citation Analysis]
|
